Website profile

Indian Pharma Post

Ajanta Pharma to hold 47th annual general meeting on July 16 Indian Pharma Post Get the latest News & Research on Pharma industry, Viewpoints, Events, Videos, statistics, indianpharmapost.com

  • 189articles · 30d
  • 8+ hour agolatest article
  • Aug 14, 2026earliest in window
  • 89%with images
  • 245avg words
articles per day
Categories
  • Medical 139
  • Health & Wellness 102
  • Economy, Business & Finance 81
  • Health 75
  • Business & Industrial 65
  • Finance & Business 33
  • Science & Technology 21
  • News 15
Bylines

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

@pharma_indian
indianpharmapost.com > clinical-trials > novo-nordisk-trial-finds-semaglutide-cuts-obesity-in-children-aged-611-21773

Novo Nordisk trial finds semaglutide cuts obesity in children aged 6–11

3+ day, 23+ hour ago   (63+ words) The findings are particularly significant because the trial population had a high burden of severe obesity Novo Nordisk trial finds semaglutide cuts obesity in children aged 6–11 MED-EL launches SONNET 3 cochlear implant audio processor in India Apollo Hospitals Navi Mumbai launches…...

@pharma_indian
indianpharmapost.com > medical-device > smt-enters-canadian-market-with-health-canada-licence-for-supraflex-cruz-coronary-stent-21777

SMT enters Canadian market with Health Canada licence for Supraflex Cruz coronary stent

3+ day, 16+ hour ago   (430+ words) Sahajanand Medical Technologies Limited (SMT) has received a Class IV medical device licence from Health Canada’s Medical Devices Directorate for its Supraflex Cruz sirolimus-eluting coronary stent system, marking the company’s entry into the Canadian market. The family licence covers the…...

@pharma_indian
indianpharmapost.com > clinical-trials > novartis-pelacarsen-trial-fails-to-cut-cardiovascular-risk-21756

Novartis’ pelacarsen trial fails to cut cardiovascular risk

4+ day, 22+ hour ago   (54+ words) The pivotal cardiovascular outcomes trial did not meet its primary endpoint FDA moves to boost estradiol patch supply as demand surges Superluminal Medicines raises $60 million to push obesity drug into clinic Novartis’ pelacarsen trial fails to cut cardiovascular risk Indian…...

@pharma_indian
indianpharmapost.com > news > superluminal-medicines-raises-60-million-to-push-obesity-drug-into-clinic-21755

Superluminal Medicines raises $60 million to push obesity drug into clinic

5+ day, 3+ hour ago   (62+ words) Indian Pharma Post Superluminal Medicines raises $60 million to push obesity drug into clinic Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants Implementing a digital transformation in chemical operations to maximize profitability The complexity of compliance The…...

Google News
indianpharmapost.com > clinical-trials > summits-ivonescimab-delivers-overall-survival-win-against-pembrolizumab-in-phase-iii-lung-cancer-trial-21732

Summit’s ivonescimab delivers overall survival win against pembrolizumab in Phase III lung cancer trial

6+ day, 22+ hour ago   (68+ words) Indian Pharma Post Summit’s ivonescimab delivers overall survival win against pembrolizumab in Phase III lung cancer trial Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants Implementing a digital transformation in chemical operations to maximize profitability The…...

@pharma_indian
indianpharmapost.com > news > gan-lee-signs-up-to-726-million-menarini-deal-for-obesity-drug-in-europe-21733

Gan & Lee signs up to €726 million Menarini deal for obesity drug in Europe

1+ week, 4+ hour ago   (61+ words) The deal gives Gan & Lee a major European partner as the Chinese pharmaceutical company seeks to turn bofanglutide into a global metabolic-health product Priyanka Tewari appointed Head of Marketing at Glenmark Pharma Sonika Natalkar joins Lupin as Deputy General Manager…...

@pharma_indian
indianpharmapost.com > clinical-trials > lillys-taltz-zepbound-combination-delivers-stronger-one-year-results-in-psoriatic-disease-obesity-trials-21655

Lilly’s Taltz-Zepbound combination delivers stronger one-year results in psoriatic disease & obesity trials

1+ week, 5+ day ago   (85+ words) indianpharmapost.com Lilly’s Taltz-Zepbound combination delivers stronger one-year results in psoriatic disease & obesity trials The results build on statistically superior outcomes reported at Week 36, when the combination outperformed Taltz alone on key disease and metabolic measures Chasing Consistency: Centralizing operations…...

@pharma_indian
indianpharmapost.com > biotech > lilly-to-acquire-merida-biosciences-for-2875-billion-in-autoimmune-disease-push-21653

Lilly to acquire Merida Biosciences for $2.875 billion in autoimmune disease push

1+ week, 5+ day ago   (65+ words) Merida's lead drug candidate, MER511, is already being tested in a Phase 1 trial for Graves' disease and thyroid eye disease Lilly to acquire Merida Biosciences for $2.875 billion in autoimmune disease push Sun Pharma joins White House push on US drug pricing…...

@pharma_indian
indianpharmapost.com > news > aurobindo-pharma-subsidiary-launches-generic-advair-diskus-in-us-21636

Aurobindo Pharma subsidiary launches generic Advair Diskus in US

1+ week, 6+ day ago   (207+ words) Lannett company commercialises first product from its inhalation pipeline in two strengths Aurobindo Pharma USA’s wholly owned subsidiary Lannett Company LLC has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in the US market. The…...

@pharma_indian
indianpharmapost.com > clinical-trials > zydus-saroglitazar-mg-clears-key-hurdle-in-global-mash-trial-21637

Zydus’ Saroglitazar Mg clears key hurdle in global MASH trial

1+ week, 6+ day ago   (73+ words) EVIDENCES-X trial met its primary endpoint, with a 26.5% treatment difference in MASH resolution without worsening of fibrosis Dr. Rajesh Nair appointed CEO of Park Group of Hospitals India cuts malaria cases and deaths by nearly 80% over a decade IPC launches…...